News Releases

Vyaire Medical Debuts New Corporate Brand Affirming Commitment to Innovation that Enhances Quality of Breathing

April 14, 2021

New Look Reflects Longstanding Legacy of Respiratory Care and Elevates Passion, Ingenuity and Dedication to Improving the Quality of Every Breath CHICAGO, April 14, 2021—Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the launch of its new corporate brand identity as part of its transformational efforts to rapidly innovate leading-edge products and services that enable, enhance and extend every breath. “Breathing is instinctual and too often we take for granted the importance until there is an issue,” said Gaurav Agarwal, chief executive officer of Vyaire. “As the past year has shown, every single breath is vital to the health and well-being of people of all ages. Our new brand identity is meant to acknowledge that notion and reflect the passion and urgency Vyaire brings to market through solutions that enhance and support breathing through every stage of life.” As We Live and Breathe The breadth and scale of the Vyaire portfolio is unmatched anywhere in the world. The Company’s new tagline highlights Vyaire’s leadership beyond the traditional respiratory space, signaling the broadest portfolio of breathing solutions supporting the care continuum from diagnostics to consumables to ventilation. More than that, it demonstrates a renewed commitment to clinicians that Vyaire is a trusted partner in their quest to advance the science of breathing and improve outcomes for their patients. “As we live and breathe” is an homage to patients, that Vyaire is here to ensure that every day — and every breath — is lived to the fullest. It’s also a pledge to healthcare professionals who care for patients that Vyaire provides products to help enable and ensure optimal breathing. The revitalized brand identity features a refreshed logo, new brand hallmark and a bold new color palette. The new brand hallmark represents the lungs, a subtle reminder of the Company’s purpose; the gradients of red and blue evoke leadership, passion, urgency and trust. As part of the reboot, Vyaire is debuting a new corporate marketing campaign, “Because I Can Breathe,” which pays tribute to how better breathing empowers people to pursue their passions and achieve their goals. Vyaire is launching a new corporate website to showcase the “Because I Can Breathe” campaign and new brand identity. The updates mark a significant milestone for Vyaire as it evolves from a 65-year history of pioneering technology from well-known respiratory brands into a unified global organization solely dedicated to breathing. “Our new brand identity signals an exciting new era for Vyaire,” continued Agarwal. “It is much more than a cosmetic change – it represents the drive and determination of close to 5,000 employees around the globe working to drive innovation because we know that our customers and their patients require the best solutions. I want our new identity to reflect that urgency and the creativity my colleagues bring to the work they do every day.” About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Medical Advances into Artificial Intelligence-Supported Respiratory Diagnostics with New Tool

April 7, 2021

CHICAGO, April 07, 2021—Vyaire Medical today announced the European launch of ArtiQ.PFT, an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). The technology’s algorithms detected disease pattern in 82 percent of cases, compared to 45 percent by pulmonologists, according to a multi-center study published in the European Respiratory Journal.[1] “Vyaire is at the forefront of incorporating the latest digital technology to ensure people’s breathing needs are met,” said Gaurav Agarwal, chief executive officer of Vyaire. “By introducing this technology, we can help clinicians feel confident in their diagnosis at the outset, enhancing their patients’ care from the start.” ArtiQ.PFT is the first cloud-based PFT-solution that leverages artificial intelligence. Prior to ArtiQ.PFT, pulmonologists spent a significant number of hours each week interpreting lengthy data to establish a diagnosis. This technology provides a standardized and unbiased diagnostic interpretation in seconds, allowing clinicians to focus on clinical decision making and patient consult. “Getting to the right treatment plan as soon as possible is critical for patients, and this technology helps clinicians reduce redundant testing and get people the care they need faster,” said Michael Pedro, M.D., vice president and medical director of Vyaire. “ArtiQ.PFT can help minimize time lost due to misdiagnosis, the ramifications of which are significant, particularly as we look ahead to a potential increase of individuals with long-term lung damage as a result of the COVID-19 pandemic.” Through a partnership with Belgian-based ArtiQ, ArtiQ.PFT is now integrated into SentrySuite™ in Europe, the software platform for all Vyntus™ Pulmonary Function Systems. SentrySuite provides an automated workflow process that seamlessly connects with existing networks and clinical infrastructures. About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Medical Launches Novel Remote AioCare Mobile Spirometer

March 16, 2021

CHICAGO, March 16, 2021—Vyaire Medical today announced the launch of the AioCare (HealthUp SA, Poland) mobile spirometry system in more than 15 countries across Europe, the Middle East, and Australia. This clinically proven technology expands upon Vyaire’s deep respiratory diagnostics expertise and allows physicians to promptly diagnose pulmonary diseases including asthma and COPD as accurately as hospital-grade spirometers. It also performs high-quality patient monitoring via advanced digital connectivity at home. “At Vyaire we are committed to advancing respiratory care, delivering new innovation that expands the clinician’s ability to diagnose and treat breathing disorders,” said Gaurav Agarwal, chief executive officer of Vyaire. “The AioCare mobile spirometry system is the latest example of our determination to enhance patients’ lives with new, easy-to-use technology that offers digitally-connected monitoring and care for chronic respiratory diseases in the comfort of their homes.” “Early diagnosis of COPD is critical to preventing disease escalation and maintaining patients’ quality of life, but many general practitioners and primary care physicians find it difficult to diagnose. AioCare’s algorithm guides physicians and provides them with confidence,” said Michael Pedro, M.D., vice president and medical director of Vyaire. “Further, at-home monitoring is critical for providing patients safe and continuous care at home, particularly now in the midst of the COVID-19 pandemic.” AioCare consists of a portable spirometer connected to a dedicated smartphone app and an online panel that allows physicians and patients to share and discuss results through remote tracking and secure communication. Dedicated algorithms measure lung parameters and symptoms and provide real-time results, allowing chronic respiratory patients to avoid unexpected consequences of disease exacerbation when self-monitoring. The AioCare digital health technology will also integrate with Vyaire’s SentrySuiteTM software platform, offering healthcare providers more context and information about each patient’s unique respiratory condition. Worldwide, an estimated 251 million COPD patients and 339 million asthma patients are undiagnosed. Asthma and COPD put enormous economic burdens on healthcare systems across the globe. Having the right tools to assist in early diagnosis and ongoing treatment are critical to reducing those costs. Under the agreement with HealthUp SA, Vyaire will begin distributing AioCare in the first 15 countries this month, with additional market registrations pending. About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Signs Framework Contract with European Commission for Delivery of Ventilators in Response to COVID-19 Pandemic

May 14, 2020

CHICAGO – May 14, 2020 – Vyaire Medical Inc., the world’s largest healthcare company fully dedicated to respiratory care, announced today that Vyaire has been selected by the European Commission as a supplier of priority medical equipment to help address the COVID-19 pandemic. Under a framework contract Vyaire will be providing ventilators to EU Member States. The framework contract runs for 12 months and allows for the purchase of approximately 26,200 ventilators in total, based on ordering by the Member States. “Vyaire is meeting the global challenge posed by the COVID-19 pandemic, working hand in glove with governments around the world to ensure an adequate supply of ventilators and associated equipment immediately and in the months to come,” said CEO Gaurav Agarwal. “This framework contract offers a seamless purchasing path for EU member states to increase their supply of critical ventilation equipment needed as the COVID-19 pandemic evolves.” Vyaire participated in a European Commission tender seeking production of invasive and non-invasive ventilators, including its bellavista™ and bellavista™ 1000e models. Early in the crisis, Vyaire responded quickly to the urgent needs in Europe by leveraging its global distribution network to deliver bellavista™ units to the hard-hit areas at the center of the outbreak. Since then, Vyaire has been working closely with governments around the globe, suppliers and manufacturing partners to considerably increase production capacity to meet the needs of the pandemic. Vyaire’s center of European operations is based in Basingstoke, England, and the company has direct presence in six other EU countries. Its workforce within the EU consists of more than 500 people and 100 business partners and distributors.  About Vyaire Medical: Vyaire is one of the largest global manufacturers of invasive and noninvasive ventilators and other breathing equipment purely focused on delivering solutions for respiratory care. Vyaire has been selected by the European Commission as a supplier of priority medical equipment to help address the COVID-19 pandemic, including as many as 26,200 bellavista™ ventilators and associated consumable products.  Vyaire has been present in Europe since 1954 with manufacturing in Krugzell and Höchberg, Germany and Hirzel and Buchs, Switzerland with research and innovation centers based in Höchberg, Germany, Hirzel, Switzerland and Helsinki, Finland. The bellavista™ ventilation portfolio offers hospitals a comprehensive solution with integration of high flow oxygen therapy and advanced synchrony support for neonatal to adult patients in a single device. Clinicians can rapidly change therapies on a broad range of patients in an effortless way.  Vyaire sells its products in all 27 EU member states and more than 100 countries globally outside of the United States, through a direct sales force, and indirect sales channels, fulfilled by its network of more than 400 distributors and business partners. For more information, please visit our website, which will be updated as our pandemic response evolves: Vyaire COVID-19 Response Center. About Vyaire Medical Vyaire Medical Inc., a global company dedicated to respiratory care, enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company consists of a conglomeration of well-known brands and was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continuum of care. Headquartered in suburban Chicago, Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands — including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide. Learn more at www.vyaire.com. Contact Cheston Turbyfill VP Corporate Communications Email: Cheston.Turbyfill@vyaire.com

Vyaire Medical and Spirit AeroSystems Partner to Greatly Increase Ventilator Production in Response to COVID-19 Pandemic

May 4, 2020

CHICAGO and WICHITA, KAN.,– May 4, 2020 – Vyaire Medical Inc., the world’s largest healthcare company fully dedicated to respiratory care, together with Spirit AeroSystems [NYSE: SPR], announced today a new manufacturing and supply collaboration to build critical care ventilators at a converted facility in Wichita, Kan. The temporary special partnership will allow Vyaire to quickly ramp up production of critical care ventilators. This partnership furthers earlier action taken by Vyaire to accelerate production of ventilators and other related respiratory equipment at its primary production facilities based in North America. “The COVID-19 pandemic has upended our way of life, but this is our opportunity to meet the needs of the American people with this partnership,” said Vyaire CEO Gaurav Agarwal. “Spirit’s breadth of technical capability, manufacturing prowess and skilled workforce make them ideally suited to support us in scaling our operations to meet this unprecedented demand. On behalf of the entire Vyaire team, I welcome the professionals from Spirit who join us in this cause and extend a deep appreciation for the job they will undertake at this critical time.” Spirit AeroSystems is one of the world’s largest non-OEM designers and manufacturers of aerostructures for commercial and defense aircraft and is headquartered in Wichita. “This collaboration is an opportunity for Spirit to help at a time when our nation needs it most,” said Tom Gentile, President and CEO of Spirit AeroSystems. “We are honored to bring our industrial capabilities and skilled workforce to help Vyaire scale up quickly to produce much-needed ventilators during this pandemic.” Spirit has expertise with industrializing and building at high production rates and has a large, well-trained and experienced workforce of assembly mechanics, machinists, factory managers and supply chain professionals already working to support conversion of manufacturing to medical devices. Design of the production system is underway, and teams are readying the facilities with production materials, critical equipment and building infrastructure to stand up manufacturing lines. Training of staff is proceeding and approximately 700 Spirit employees will be assigned to this special project as production ramps up. The Vyaire/Spirit AeroSystems collaboration is a meaningful action to meet unprecedented demand for ventilation equipment in the face of the COVID-19 pandemic. Vyaire was chosen by the U.S. Department of Health and Human Services (HHS) to provide 22,000 of its LTV2 2200 ventilators to the U.S. Strategic National Stockpile. In addition to the national stockpile request, Vyaire is working with state and private hospital and health system clients to ensure delivery of ventilators to areas of greatest need. The manufacturing and supply collaboration will help to balance the needs of clinicians urgently treating patients at the bedside with the commitment to fill or replenish strategic stockpiles. Vyaire is working with customers, including the HHS, to ensure patient need is prioritized and that critical care ventilators are distributed to areas in most need. It is anticipated that more than 1,000 American workers, approximately 700 from Spirit and 300 from Vyaire, will be working in facilities in California and Kansas to manufacture ventilators at the height of this collaboration. For more information, please visit our website, which will be updated as our pandemic response evolves: Vyaire COVID-19 Response Center. About Vyaire Medical Vyaire Medical Inc., a global company dedicated to respiratory care, enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company consists of a conglomeration of well-known brands and was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continuum of care. Headquartered in suburban Chicago, Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands — including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide. Learn more at www.vyaire.com. About Spirit AeroSystems Spirit AeroSystems designs and builds aerostructures for both commercial and defense customers. With headquarters in Wichita, Kansas, Spirit operates sites in the U.S., U.K., France and Malaysia. The company's core products include fuselages, pylons, nacelles and wing components for the world's premier aircraft. Spirit AeroSystems focuses on affordable, innovative composite and aluminum manufacturing solutions to support customers around the globe. More information is available at www.spiritaero.com. Contact For Vyaire Medical Cheston Turbyfill Email: Cheston.Turbyfill@vyaire.com For Spirit AeroSystems, Inc. Keturah Austin Email: Keturah.austin@spiritaero.com  

Vyaire To Produce 4,300 Ventilators for Brazil at Company’s Sao Paulo Facility

April 28, 2020

CHICAGO – April 28, 2020 – Vyaire Medical, the world’s largest healthcare company fully dedicated to respiratory care, announced the Brazilian Ministry of Health has awarded the company a USD $50 million (BR $258 million) contract to produce 4,300 iX5™ ventilators by the end of June in response to the coronavirus (COVID-19) pandemic. “We at Vyaire are proud of our company’s deep roots in Brazil and a legacy of nearly forty years of supporting the respiratory health needs of the Brazilian people directly from our base of operations near Sao Paulo,” said CEO Gaurav Agarwal. “We are well-positioned to leverage our global scale and undisputed expertise to work with the Brazilian Ministry of Health to deliver ventilators as part of its response to the global COVID-19 pandemic,” said Agarwal. “We thank the Brazilian government for their partnership and confidence as we continue our effort to ramp up manufacturing capacity globally to ensure an adequate supply of ventilators and associated consumables at this critical time.”   Vyaire has taken many preparative steps in order to meet the demands created by the increased need for ventilators in Brazil; including, reconfiguring the factory lay out for the manufacturing facility in Cotia and forming strategic partnerships with local companies for assistance with subassembly work. To accommodate the increased workload, Vyaire has retained outside resources to expand its focus on process optimization and project management as well as hired additional workers for new manufacturing shifts. These steps were taken in concert with Vyaire’s global expansion of manufacturing output to deal with the demands of the COVID-19 pandemic. About Vyaire Medical: Vyaire is one of the largest global manufacturers of invasive ventilators and other breathing equipment and is one of the first healthcare company to obtain ISO 9000 certification in Brazil for medical devices. The Brazilian Ministry of Health will be supplied with 4,300 iX5™ ventilators manufactured at the company’s facility in Cotia, Sao Paulo. Vyaire has been producing ventilators in Brazil since 1987, formerly operated under the brand Intermed, and is the main supplier for intensive care ventilation equipment for the country. The iX5™ ventilator is a multifunctional device offering clinicians an economical solution to help improve patient outcomes. The compact and intuitive ventilator offers invasive and non-invasive solutions from neonates to adults, including lung protective Infant Flow and TGI technology. Complimenting Vyaire’s robust manufacturing presence in Brazil, the company has a strong and experienced team of distributors in all states of the country ensuring ready access of these products to all areas. For more information, please visit our website at www.vyaire.com About Vyaire Medical Vyaire Medical Inc., a global company dedicated to respiratory care, enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company consists of a conglomeration of well-known brands and was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continuum of care. Headquartered in suburban Chicago, Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide.

Vyaire Medical Steps Up Operations in Response to Coronavirus Pandemic

April 3, 2020

CHICAGO – April 3, 2020 – Vyaire Medical, Inc. and CEO Gaurav Agarwal today issued the following update on the company’s response to the coronavirus (COVID-19) pandemic: “Vyaire Medical is committed to partnering with public health, government and medical frontline responders to combat the threat of the coronavirus pandemic. Our global team is working tirelessly to deliver and accelerate access to essential medical equipment for patients in respiratory distress due to COVID-19 and to the healthcare workers treating them,” said CEO Gaurav Agarwal. Beginning in January, Vyaire -- the largest company in the global healthcare ecosystem fully dedicated to respiratory care -- began the process of retooling its manufacturing capacity to meet the emerging global need and the expected surge in demand for ventilation equipment as the medical community responded to the evolving nature of the COVID-19 pandemic. “In January, we initiated a proactive strategy to expand our manufacturing capabilities and begin to scale our workforce to dramatically increase the volume of new ventilators and accompanying equipment, such as circuits, filters and water traps,” Agarwal said. “Our goal was to increase our output exponentially, and as quickly as possible, to help frontline responders and health systems manage and treat critical conditions due to COVID-19.” Vyaire has been in close consultation with public and government healthcare responders to align, prioritize, scale and mobilize quickly as the crisis evolves around the world. Among other strategies, the company is redeploying engineering resources and seeking to hire additional workforce to accelerate production of ventilators at key manufacturing facilities. In addition, the company is exploring potential partnerships with non-medical equipment manufacturers and distribution companies to increase the availability of life-saving equipment and speed access to areas of the country in most critical need. Vyaire’s broad range of products provide solutions across specialties that span the continuum of care, including Critical Care, Emergency Medicine, Infection Control and Prevention, Pulmonology and Respiratory Therapy. Proactive planning and risk mitigation activities are ongoing to reduce risk and ensure consistent access to Vyaire’s products. The company has implemented immediate actions, including: Robust preventive measures to ensure our manufacturing facilities remain fully operational and our employees stay safe. To prevent community spread in manufacturing facilities, Vyaire increased hygiene protocols, ensured employees have the latest guidance from the CDC, WHO and other public health agencies, limited visitors to its manufacturing sites and allowed those who can work remotely to do so. The company also established an internal team that is actively monitoring and determining the appropriate measures to help guide ongoing policies and actions as the public health crisis evolves. Close coordination with global suppliers to ensure access to necessary supplies is safe and secure. Vyaire is advocating that the global supply chain remain open and uninterrupted, particularly as other non-medical manufacturers are called upon to begin making respiratory equipment, so there is adequate access to necessary components to match increased production of ventilators. Flexibility in fulfillment processes to prioritize bedside delivery. In close consultation with customers, the public health community and federal and state governments, Vyaire is prioritizing and aligning the delivery of its respiratory solutions to those in most critical need, including hospitals in hotspot areas. “Vyaire has a long history of clinical excellence, leadership and expertise in treating and monitoring respiratory conditions in every stage of life. Today, in response to the coronavirus pandemic, our passionate, dedicated global workforce is fulfilling our commitment to quality and accountability as we focus on supporting life by delivering critical equipment to those who need it most,” said Agarwal. Vyaire has raised incremental financing, led by Bank of America and Royal Bank of Canada, with the support of existing investors including GSO, Symphony Asset Management, Blackrock and MVCredit.  The new investment round will enable Vyaire to further capitalize on its position as largest company in the global healthcare ecosystem fully dedicated to respiratory care, and its efforts to rapidly respond to the unprecedented demand for ventilators and accompanying equipment.  For more information, please visit our website, which will be updated as our pandemic response evolves: Vyaire COVID-19 Response Center. About Vyaire Medical Headquartered in suburban Chicago, Vyaire Medical – a global company dedicated to respiratory care — enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continua of care. Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide. Learn more at www.vyaire.com. Contact Cheston Turbyfill VP Corporate Communications Email: Cheston.Turbyfill@vyaire.com

Asthma Monitoring Device Fenom Pro® Meets Clinical Precision Standards for Measuring Nitric Oxide in Adults and Children

March 4, 2020

CHICAGO and PLEASANTON, Calif. — March 4, 2020 ― Research published in the January 2020 issue of the Journal of Breath Research found Spirosure’s Fenom Pro® Asthma monitor provides a clinically precise measurement of Fractional exhaled Nitric Oxide (FeNO) in adults and children with asthma. The study also showed that either one six-second or one ten-second exhalation was adequate to obtain a clinically relevant and precise measurement.  “Fenom Pro gives healthcare providers a new choice for accurate FeNO measurement with shorter test times than NIOX VERO. In this study it met clinical precision needs and had excellent analytical precision when compared to the gold-standard of ozone chemiluminescence,” said Vivek Balasubramanyam, Vice President, Sales and Marketing, Spirosure. “We hope that accurate and easy FeNO measurements will help physicians improve asthma control by responding to changes in inflammation before they develop into symptoms.” FeNO is the most established biomarker for diagnosing asthma. It can also be measured to confirm response to medications that target eosinophilic inflammation and identify suboptimal medication compliance.  The 2005 American Thoracic Society recommendations call for the average of two, 10-second exhalations to accurately measure nitric oxide. The European Respiratory Society technical standards propose one valid exhalation. This study shows that Fenom Pro can meet both organizations’ guidance for asthma monitoring.     “Adding FeNO to Vyaire’s comprehensive line of pulmonary function testing equipment helps us offer a state-of-the-art respiratory diagnostic suite,” said Gaurav Agarwal, CEO, Vyaire Medical. “Fenom Pro improves clinicians speed and accuracy when diagnosing asthma and keeping it under control.” To evaluate the clinical precision of Fenom Pro in adults and children, researchers compared six and 10-second patient exhalations using NIOX VERO and Fenom Pro at three U.S. clinical research sites. During a single visit, each subject’s first FeNO measure (via exhalation) on Fenom Pro was compared to the average of the two FeNO measures on NIOX VERO. The study was done with 100 participants including 60 adults and 40 children who had clinically stable asthma, who had not smoked in the last six months, and had a less than 10-year history of smoking and otherwise stable respiratory health.   About Fenom Pro Fenom Pro offers the fastest test time among similar devices available in the U.S. and requires the least amount of maintenance among similar devices. The measurements obtained from Fenom Pro can assist in evaluating treatment response for certain conditions, such as asthma. Data from Fenom Pro will also integrate with Vyaire’s SentrySuite® software platform, offering healthcare providers more context and information about each patient’s unique respiratory condition.  About FeNO Nitric Oxide (NO) is produced in the lungs and becomes more concentrated when the lungs are inflamed due to allergic asthma. FeNO is a standardized measure of this concentration and provides a quick and non-invasive biomarker for airway inflammation. Measurement of FeNO helps assess the need for anti-inflammatory medication and supports ongoing monitoring of anti-inflammatory therapy for conditions like asthma. Routine FeNO testing can help allergists, pulmonologists and respiratory therapists determine the best treatment path, and avoid potentially unnecessary medicines.  About SPIROSURE Spirosure Inc. was founded in 2011 in Pleasanton, California by Dr. Solomon Ssenyange and Ryan Leard. It is focused on improving quality of life for the 300 million people around the world who have asthma by offering tools that enable proactive intervention. In recent years, non-invasive measurement and monitoring of the fraction of exhaled nitric oxide (FeNO) in exhaled breath has become established as the biomarker of asthma. Learn more at spirosure.com and fenomasthma.com. About Vyaire Medical  Headquartered near Chicago, IL., Vyaire Medical - a global company dedicated to respiratory care — enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continua of care.  Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide. Learn more at www.vyaire.com.

2 of 4